LOGIN  |  REGISTER
Amneal Pharmaceuticals

Auna Announces the Filing of Its Form 20-F for the Fiscal Year 2024

April 10, 2025 | Last Trade: US$6.71 0.08 1.21

LUXEMBOURG / Apr 10, 2025 / Business Wire / Auna S.A. (“Auna” or the “Company”) (NYSE: AUNA), a Latin American healthcare company with operations in Mexico, Peru and Colombia, announced today the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission (the “SEC”) on April 10, 2025.

Auna’s Annual Report on Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the “Financial Info” section of the Company’s Investor Relations website at www.aunainvestors.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements, or its complete 2024 Form 20-F including audited financial statements, free of charge, by requesting a copy from the Investor Relations team at This email address is being protected from spambots. You need JavaScript enabled to view it.

About Auna

Auna is a leading horizontally and vertically integrated healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, focusing on high-complexity diseases. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31st, 2024, Auna’s network included 31 healthcare network facilities, including hospitals, outpatient, prevention and wellness facilities with 2,323 beds, and 1.4 million healthcare plans.

For more information visit www.aunainvestors.com

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page